TISSUE REGENIX GROUP PLC — Board/Management Information 2019

Aug 28, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 3280K

Tissue Regenix Group PLC

28 August 2019

Tissue Regenix Group plc

Appointment of CFO

Leeds, 28 August 2019 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or the "Group"), the regenerative medical devices company, announces the appointment of Mike Barker as Chief Financial Officer (CFO).  Mike will join the Group as CFO and as an Executive Director on the Board with immediate effect having supported Tissue Regenix since the beginning of the year as interim Finance Director. 

A Chartered Accountant for over 20 years, Mike has experience of both AIM listed and private businesses. After training with Deloitte, he spent 10 years in their corporate finance advisory business working extensively on private equity transactions before setting up his own consultancy business to assist SME's in the delivery of their strategic plans. During this time, he worked closely with the management team of Quantum Pharma plc, a UK manufacturer and supplier of unlicensed medicines and hard-to-source products (acquired by Clinigen Group plc in 2017), to deliver strategic projects before holding the position of Group Corporate Development Director.

Full details of Mike's current and past directorships are provided below.  

John Samuel, Executive Chairman, Tissue Regenix Group plc, commented: 

"It's a pleasure to welcome Mike to the Executive team. He is well acquainted with the business, having supported the Group since the beginning of the year. His experience in AIM listed businesses and contribution to strategic planning will augment and strengthen our management and Executive teams as we continue to improve the efficiency of our operations across the business to meet the increasing demand for our products."

For more information:

Tissue Regenix Group plc Caitlin Pearson, Head of Communications	Tel: 0330 430 3073 / 07920272441
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker) Jonathan Senior / Alex Price / Ben Maddison	Tel:  0207 710 7600
FTI Consulting  Brett Pollard / Victoria Foster Mitchell / Mary Whittow	Tel: 0203 727 1000

Regulatory disclosures

Michael (Mike) Denis Barker, aged 43 

Current directorships:	Directorships in the last 5 years:
TimeC 1306 Limited	Quantum Pharma Group Limited
Barker Advisory Limited	Quantum Pharmaceutical Limited
Rhythm Time (Newcastle) LLP	Nupharm Laboratories Limited
Cambridge Scholars Publishing Ltd	Nupharm Group Limited
Ridge Pharma Ltd

There is no further information to be disclosed in accordance with the requirements of Schedule Two paragraph (g) of the AIM rules.

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

BOAPGUWWRUPBGRM